Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    BioCryst Pharmaceuticals ...

    NASDAQ: BCRX · Real-Time Price · USD
    8.94
    -0.08 (-0.89%)
    At close: Jul 03, 2025, 12:59 PM
    8.94
    0.00%
    After-hours: Jul 03, 2025, 04:38 PM EDT

    BioCryst Pharmaceuticals Statistics

    Share Statistics

    BioCryst Pharmaceuticals has 209.25M shares outstanding. The number of shares has increased by 1.14% in one year.

    Shares Outstanding

    n/a
    		 209.25M

    Shares Change (YoY)

    n/a
    		 1.14%

    Shares Change (QoQ)

    n/a
    		 0.14%

    Owned by Institutions (%)

    n/a
    		 81.05%

    Shares Floating

    n/a
    		 200.37M

    Failed to Deliver (FTD) Shares

    n/a
    		 347

    FTD / Avg. Volume

    n/a
    		 0.01%

    Short Selling Information

    The latest short interest is 23.08M, so 11.03% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 23.08M

    Short % of Shares Out

    n/a
    		 11.03%

    Short % of Float

    n/a
    		 11.07%

    Short Ratio (days to cover)

    n/a
    		 6.65

    Valuation Ratios

    The PE ratio is -17.49 and the forward PE ratio is 23.17. BioCryst Pharmaceuticals's PEG ratio is 0.28.

    PE Ratio

    n/a
    		 -17.49

    Forward PE

    n/a
    		 23.17

    PS Ratio

    n/a
    		 3.45

    Forward PS

    n/a
    		 1.9

    PB Ratio

    n/a
    		 -3.27

    P/FCF Ratio

    n/a
    		 -29.25

    PEG Ratio

    n/a
    		 0.28
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for BioCryst Pharmaceuticals.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 2.63, with a Debt / Equity ratio of -1.7.

    Current Ratio

    n/a
    		 2.63

    Quick Ratio

    n/a
    		 2.58

    Debt / Equity

    n/a
    		 -1.7

    Debt / EBITDA

    n/a
    		 63.14

    Debt / FCF

    n/a
    		 -15.22

    Interest Coverage

    n/a
    		 -0.03

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $777,089.66

    Profits Per Employee

    n/a
    		 $-153,243.1

    Employee Count

    n/a
    		 580

    Asset Turnover

    n/a
    		 0.92

    Inventory Turnover

    n/a
    		 1.52

    Taxes

    Income Tax

    n/a
    		 1.93M

    Effective Tax Rate

    n/a
    		 -2.22%

    Stock Price Statistics

    The stock price has increased by 39.47% in the last 52 weeks. The beta is 1.1, so BioCryst Pharmaceuticals's price volatility has been higher than the market average.

    Beta

    n/a
    		 1.1

    52-Week Price Change

    n/a
    		 39.47%

    50-Day Moving Average

    n/a
    		 9.96

    200-Day Moving Average

    n/a
    		 8.3

    Relative Strength Index (RSI)

    n/a
    		 29.78

    Average Volume (20 Days)

    n/a
    		 4,771,203

    Income Statement

    In the last 12 months, BioCryst Pharmaceuticals had revenue of 450.71M and earned -88.88M in profits. Earnings per share was -0.43.

    Revenue

    n/a
    		 450.71M

    Gross Profit

    n/a
    		 438.44M

    Operating Income

    n/a
    		 -2.54M

    Net Income

    n/a
    		 -88.88M

    EBITDA

    n/a
    		 12.81M

    EBIT

    n/a
    		 11.56M

    Earnings Per Share (EPS)

    n/a
    		 -0.43
    Full Income Statement

    Balance Sheet

    The company has 104.71M in cash and 808.74M in debt, giving a net cash position of -704.03M.

    Cash & Cash Equivalents

    n/a
    		 104.71M

    Total Debt

    n/a
    		 808.74M

    Net Cash

    n/a
    		 -704.03M

    Retained Earnings

    n/a
    		 -1.77B

    Total Assets

    n/a
    		 480.05M

    Working Capital

    n/a
    		 269.18M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -52.02M and capital expenditures -1.12M, giving a free cash flow of -53.14M.

    Operating Cash Flow

    n/a
    		 -52.02M

    Capital Expenditures

    n/a
    		 -1.12M

    Free Cash Flow

    n/a
    		 -53.14M

    FCF Per Share

    n/a
    		 -0.26
    Full Cash Flow Statement

    Margins

    Gross margin is 97.28%, with operating and profit margins of -0.56% and -19.72%.

    Gross Margin

    n/a
    		 97.28%

    Operating Margin

    n/a
    		 -0.56%

    Pretax Margin

    n/a
    		 -19.29%

    Profit Margin

    n/a
    		 -19.72%

    EBITDA Margin

    n/a
    		 2.84%

    EBIT Margin

    n/a
    		 -0.56%

    FCF Margin

    n/a
    		 -11.79%

    Dividends & Yields

    BCRX does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for BCRX is $16, which is 79% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $16

    Price Target Difference

    n/a
    		 79%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 11
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 -1.75

    Piotroski F-Score

    n/a
    		 3

    Add to Watchlist